Skip to content
Menu

Takeda Pharmaceutical Company Limited TAK

Full chart Compare
Set alert

Price alert · TAK

All alert types
21.90 USD +0.48 (+2.27%)

As ofNov 20, 2026, 3:19 PM EST

21.81 Day range 22.07
14.09 52-week range 22.07
YTD
+40.44%
1 year
+55.73%

5D +0.07 (+0.32%)

21.2521.5021.7522MonTueWedThuFri21.90
Market cap
69.95B
Revenue (ttm)
4.69T
Profit margin
0.87%
EPS (ttm)
0.07
Shares out
3.19B
P/E ratio
312.79
Forward P/E
40.42
Dividend
0.62 (2.22%)
Ex-dividend date
Mar 31, 2026
YTD return
+40.44%
1-year return
+55.73%
Volume
2.58M
Avg volume
2.70M
Open
21.82
Previous close
21.41
Day's range
21.81 – 22.07
52-week range
14.09 – 22.07
Beta
0.08
Analysts
Strong Buy
Price target
24.51 (+11.9%)
Earnings date
Jan 28, 2027
50-day average
19.59

Key statistics

200-day average
17.84
Enterprise value
5.01T
PEG ratio
0.48
Price / sales
0.01
Price / book
1.46
Payout ratio
426.53%
Revenue growth
6.70%
Free cash flow
681.38B
Total cash
418.53B
Total debt
5.36T
Return on equity
0.56%
Short % of float
0.10%

Fundamental scorecard

12 of 25 checks passed on TAK’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 1 of 5
  • Growth 4 of 5
  • Profitability 2 of 5
  • Financial health 1 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TAK Revenue — quarterly 1.19T
TAK Net income — quarterly 192.46B
TAK EPS — quarterly 60.44

Earnings

TAK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20260.1417———
Oct 29, 2026Sep 30, 20260.310.3852+0.08+24.26%
Jul 30, 2026Jun 30, 20260.16890.225+0.06+33.21%
May 13, 2026Mar 31, 20260.21-0.04919-0.26-123.42%
Jan 29, 2026Dec 31, 20250.550.2131-0.34-61.25%
Oct 30, 2025Sep 30, 20250.44-0.02493-0.46-105.67%

Upgrades / downgrades

TAK analyst upgrades and downgrades
DateFirmActionFromTo
May 16, 2023TD CowenmainOutperformOutperform
Apr 4, 2023TD Cowenmain—Outperform
Mar 16, 2023B of A SecuritiesupNeutralBuy
Jul 19, 2022Cowen & Co.upMarket PerformOutperform
Oct 7, 2021Morgan StanleydownOverweightEqual-Weight
Mar 11, 2020JP Morganmain—Overweight

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Website
takeda.com

News

Your note

Sign in to keep a note on TAK — it syncs with the Stock Master app.

Insider holders

TAK insider holders
InsiderRelationLatest transactionDateShares held
BITETTI TERESA MARIEOfficerSaleAug 9, 2026252,010
DUPREY LAUREN RUSCKOWSKIOfficerSaleSep 13, 2026191,522
FURNEY NATALIE ANNE MARIEOfficerSaleAug 9, 2026204,298
KIM JULIE SO-YOUNGChief Executive OfficerSaleAug 9, 2026391,489
PACHECO RHONDA JANICEOfficerSaleAug 9, 2026182,507
PIGNAGNOLI AGOSTI MARCELLOOfficerSaleAug 9, 2026176,977

Institution ownership

TAK institution ownership
Holder% heldSharesValueReported
Capital Research Global Investors0.84%26,952,673577.33MSep 29, 2026
FMR, LLC0.34%10,974,215235.07MSep 29, 2026
Morgan Stanley0.26%8,234,395176.38MSep 29, 2026
Adage Capital Partners GP L.L.C.0.22%7,200,771154.24MSep 29, 2026
Goldman Sachs Group Inc0.17%5,541,243118.69MSep 29, 2026
Brandes Investment Partners L.P.0.13%4,238,82590.80MSep 29, 2026

Fund ownership

TAK fund ownership
Holder% heldSharesValueReported
AMERICAN MUTUAL FUND0.57%18,157,900388.94MSep 29, 2026
Capital Income Builder0.23%7,343,700157.30MSep 29, 2026
VanEck ETF Trust-VanEck Pharmaceutical ETF0.05%1,522,52232.61MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT Value Line Dividend Index Fd.0.05%1,714,20136.72MSep 29, 2026
GOLDMAN SACHS TRUST-Goldman Sachs Income Builder Fund0.02%494,44210.59MJul 30, 2026
Steward Funds Inc-Steward Values Enhanced International Fund0.02%711,87115.25MJul 30, 2026